companydata.dkNeo Biopharm ApS: Financial statements 2024
CVR: 42875708
Neo Biopharm ApS (CVR 42875708) has filed annual accounts for 2024. In 2024, the company reported a gross profit of DKK 206,139 and a net result of DKK 157,190 compared with DKK 243,802 the year before. That is a decrease of 61% compared with the year before. Equity amounted to DKK 2,265,898. The solvency ratio was 90.2%.
- Gross Profit
- 206,139 kr.
- Profit/Loss
- 157,190 kr.
- Equity
- 2,265,898 kr.
- Total Assets
- 2,513,272 kr.
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2024 | - | 206 t. | 157 t. | 2.3 mio. | - |
| 2023 | - | 528 t. | 244 t. | 2.1 mio. | - |
How creditworthy is Neo Biopharm ApS?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2024
Neo Biopharm ApS has published its annual report for 2023. Gross profit came to DKK 528,359, and the net result was DKK 243,802.
As of March 1, 2024, Jakob Juul Rasmussen is registered as director of Neo Biopharm ApS.
As of March 1, 2024, Maryam Badri has stepped down as director of Neo Biopharm ApS.
About Neo Biopharm ApS
Neo Biopharm ApS is a Danish company of the type Anpartsselskab based in Hellerup, founded in 2021. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Jakob Juul Rasmussen. The company is owned by Maryam Badri. In 2025, the company reported a gross profit of DKK -357,308 and a net result of DKK -271,403 compared with DKK 157,190 the year before. Equity amounted to DKK 1,994,496.